These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 33400854)
81. The Lysine Methylase SMYD3 Modulates Mesendodermal Commitment during Development. Fittipaldi R; Floris P; Proserpio V; Cotelli F; Beltrame M; Caretti G Cells; 2021 May; 10(5):. PubMed ID: 34069776 [TBL] [Abstract][Full Text] [Related]
82. SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters. Lyu T; Jiang Y; Jia N; Che X; Li Q; Yu Y; Hua K; Bast RC; Feng W Int J Cancer; 2020 Mar; 146(6):1553-1567. PubMed ID: 31503345 [TBL] [Abstract][Full Text] [Related]
83. Stimulation of the weak ATPase activity of human hsp90 by a client protein. McLaughlin SH; Smith HW; Jackson SE J Mol Biol; 2002 Jan; 315(4):787-98. PubMed ID: 11812147 [TBL] [Abstract][Full Text] [Related]
84. Large scale free energy calculations for blind predictions of protein-ligand binding: the D3R Grand Challenge 2015. Deng N; Flynn WF; Xia J; Vijayan RS; Zhang B; He P; Mentes A; Gallicchio E; Levy RM J Comput Aided Mol Des; 2016 Sep; 30(9):743-751. PubMed ID: 27562018 [TBL] [Abstract][Full Text] [Related]
85. Overexpression of SMYD3 Is Predictive of Unfavorable Prognosis in Hepatocellular Carcinoma. Fei X; Ma Y; Liu X; Meng Z Tohoku J Exp Med; 2017 Nov; 243(3):219-226. PubMed ID: 29187705 [TBL] [Abstract][Full Text] [Related]
86. Subpocket analysis method for fragment-based drug discovery. Kalliokoski T; Olsson TS; Vulpetti A J Chem Inf Model; 2013 Jan; 53(1):131-41. PubMed ID: 23327721 [TBL] [Abstract][Full Text] [Related]
87. Estimation of Drug-Target Residence Times by τ-Random Acceleration Molecular Dynamics Simulations. Kokh DB; Amaral M; Bomke J; Grädler U; Musil D; Buchstaller HP; Dreyer MK; Frech M; Lowinski M; Vallee F; Bianciotto M; Rak A; Wade RC J Chem Theory Comput; 2018 Jul; 14(7):3859-3869. PubMed ID: 29768913 [TBL] [Abstract][Full Text] [Related]
88. In vitro study of enzymatic hydrolysis of diperodon enantiomers in blood serum by two-dimensional LC. Hrobonová K; Lehotay J; Cizmárik J; Armstrong DW J Pharm Biomed Anal; 2002 Oct; 30(3):875-80. PubMed ID: 12367714 [TBL] [Abstract][Full Text] [Related]
89. Targeting INMT and interrupting its methylation pathway for the treatment of castration resistant prostate cancer. Zhong S; Jeong JH; Huang C; Chen X; Dickinson SI; Dhillon J; Yang L; Luo JL J Exp Clin Cancer Res; 2021 Sep; 40(1):307. PubMed ID: 34587977 [TBL] [Abstract][Full Text] [Related]
90. SMYD3-Mediated H2A.Z.1 Methylation Promotes Cell Cycle and Cancer Proliferation. Tsai CH; Chen YJ; Yu CJ; Tzeng SR; Wu IC; Kuo WH; Lin MC; Chan NL; Wu KJ; Teng SC Cancer Res; 2016 Oct; 76(20):6043-6053. PubMed ID: 27569210 [TBL] [Abstract][Full Text] [Related]
91. SMYD3-NY, a novel SMYD3 mRNA transcript variant, may have a role in human spermatogenesis. Zhou Z; Ren X; Huang X; Lu L; Xu M; Yin L; Li J; Sha J Ann Clin Lab Sci; 2005; 35(3):270-7. PubMed ID: 16081583 [TBL] [Abstract][Full Text] [Related]
93. High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer. Wang G; Huang Y; Yang F; Tian X; Wang K; Liu L; Fan Y; Li X; Li L; Shi B; Hao Y; Xia C; Nie Q; Xin Y; Shi Z; Ma L; Xu D; Liu C Aging (Albany NY); 2020 Feb; 12(3):2030-2048. PubMed ID: 32007952 [TBL] [Abstract][Full Text] [Related]
95. Dual Binding to Orthosteric and Allosteric Sites Enhances the Anticancer Activity of a TRAP1-Targeting Drug. Hu S; Ferraro M; Thomas AP; Chung JM; Yoon NG; Seol JH; Kim S; Kim HU; An MY; Ok H; Jung HS; Ryu JH; Colombo G; Kang BH J Med Chem; 2020 Mar; 63(6):2930-2940. PubMed ID: 32068404 [TBL] [Abstract][Full Text] [Related]
96. Structural ensemble-based docking simulation and biophysical studies discovered new inhibitors of Hsp90 N-terminal domain. Kim HH; Hyun JS; Choi J; Choi KE; Jee JG; Park SJ Sci Rep; 2018 Jan; 8(1):368. PubMed ID: 29321504 [TBL] [Abstract][Full Text] [Related]
97. Allosteric Modulators of HSP90 and HSP70: Dynamics Meets Function through Structure-Based Drug Design. Ferraro M; D'Annessa I; Moroni E; Morra G; Paladino A; Rinaldi S; Compostella F; Colombo G J Med Chem; 2019 Jan; 62(1):60-87. PubMed ID: 30048133 [TBL] [Abstract][Full Text] [Related]
98. Crystal structures of histone and p53 methyltransferase SmyD2 reveal a conformational flexibility of the autoinhibitory C-terminal domain. Jiang Y; Sirinupong N; Brunzelle J; Yang Z PLoS One; 2011; 6(6):e21640. PubMed ID: 21738746 [TBL] [Abstract][Full Text] [Related]
99. HPC Analysis of Multiple Binding Sites Communication and Allosteric Modulations in Drug Design: The HSP Case Study. Chiappori F; Milanesi L; Merelli I Curr Drug Targets; 2016; 17(14):1610-1625. PubMed ID: 26648062 [TBL] [Abstract][Full Text] [Related]
100. A novel small molecule ZYZ384 targeting SMYD3 for hepatocellular carcinoma via reducing H3K4 trimethylation of the Rac1 promoter. Ding Q; Cai J; Jin L; Hu W; Song W; Rose P; Tang Z; Zhan Y; Bao L; Lei W; Zhu YZ MedComm (2020); 2024 Oct; 5(10):e711. PubMed ID: 39286779 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]